SCHEMBL5756033

SCHEMBL5756033

CCCCCCCSc1nc2ccc(S(=O)(=O)N[C@H](Cc3ccc(OCCCN4C(=O)c5ccccc5C4=O)cc3)C(=O)O)cc2s1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LDHA P00338 1/20 0.43
RXFP1 Q9HBX9 2/20 0.42
MAPT P10636 6/20 0.42
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ITGB3 P05106 5/20 0.41
ITGA2B P08514 5/20 0.41
THRB P10828 1/20 0.40
KCNA5 P22460 1/20 0.40
ITGB1 P05556 1/20 0.40
ITGA4 P13612 1/20 0.40
MMP3 P08254 1/20 0.40
MMP13 P45452 1/20 0.40
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5756506 0.94 MMP1 (0.44) LDHARXFP1MAPTPPARGPPARA
SCHEMBL5754622 0.89 LDHA (0.47) LDHARXFP1MAPTPPARGPPARA
SCHEMBL5757446 0.89 LDHA (0.47) LDHARXFP1MAPTPPARGPPARA
SCHEMBL5756805 0.87 MAPT (0.46) LDHARXFP1MAPTPPARGPPARA
SCHEMBL5754509 0.86 ITGB3 (0.46) MAPTITGB3ITGA2BALDH1A1
SCHEMBL5753452 0.85 PPARG (0.51) MAPTPPARGPPARALMNASMN1; SMN2
SCHEMBL5752915 0.85 ITGB3 (0.45) MAPTSMN1; SMN2ITGB3ITGA2BITGB1
SCHEMBL5757695 0.84 POLB (0.51) MAPTPPARGPPARALMNASMN1; SMN2
SCHEMBL5755153 0.84 LDHA (0.44) LDHARXFP1MAPTPPARGPPARA
SCHEMBL5753914 0.84 LDHA (0.44) LDHARXFP1MAPTPPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1208092-B1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2006-06-21 EP disclosed
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 EP disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 LDHA 1875/4885RXFP1 2743/4885MAPT 4046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.